Psoriasiform dermatitis following ocrelizumab in relapsing-remitting multiple sclerosis: Case report and literature review.

Emma, Callanan; Vesela, Petkova; Kay, Polly; Huseyin, Huseyin; Alison, Hassett; Mara, Sittampalam; Floriana, De Angelis; Sara, Collorone

Emma, Callanan; Vesela, Petkova; Kay, Polly; Huseyin, Huseyin; Alison, Hassett; Mara, Sittampalam; Floriana, De Angelis; Sara, Collorone.

Afiliação

Emma C; Department of Neurology, Luton and Dunstable University Hospital NHS Foundation Trust, Luton, UK.
Vesela P; Department of Neurology, Luton and Dunstable University Hospital NHS Foundation Trust, Luton, UK.
Kay P; Department of Neurology, Luton and Dunstable University Hospital NHS Foundation Trust, Luton, UK.
Huseyin H; Department of Neurology, Luton and Dunstable University Hospital NHS Foundation Trust, Luton, UK.
Alison H; Department of Neurology, Luton and Dunstable University Hospital NHS Foundation Trust, Luton, UK.
Mara S; Department of Neurology, Luton and Dunstable University Hospital NHS Foundation Trust, Luton, UK.
Floriana A; Department of Neurology, Luton and Dunstable University Hospital NHS Foundation Trust, Luton, UK.
Sara C; Queen Square MS Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK.

Mult Scler ; 30(7): 893-897, 2024 Jun.

Article em En | MEDLINE | ID: mdl-38385208

ABSTRACT

ABSTRACT

We present a case of a 30-year-old man with relapsing-remitting multiple sclerosis who developed psoriasiform dermatitis following his second course of ocrelizumab. This resolved with topical therapies and discontinuation of treatment. Cases of psoriasiform rashes have been increasingly reported in the use of ocrelizumab and are possibly due to B-cell (CD20) depletion and T-cell overregulation. Nevertheless, skin-related adverse reactions are not yet considered in the risk management plans of anti-CD20 treatments in multiple sclerosis.

Assuntos

Anticorpos Monoclonais Humanizados; Esclerose Múltipla Recidivante-Remitente; Psoríase; Humanos; Esclerose Múltipla Recidivante-Remitente/tratamento farmacológico; Anticorpos Monoclonais Humanizados/efeitos adversos; Masculino; Adulto; Psoríase/tratamento farmacológico; Psoríase/induzido quimicamente; Fatores Imunológicos/efeitos adversos; Toxidermias/etiologia; Toxidermias/patologia

Palavras-chave

Multiple sclerosis; drug monitoring; drug-related side effects and adverse reactions; ocrelizumab; psoriases

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Psoríase / Esclerose Múltipla Recidivante-Remitente / Anticorpos Monoclonais Humanizados Limite: Adult / Humans / Male Idioma: En Revista: Mult Scler Assunto da revista: NEUROLOGIA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google